DONEPEZIL HYDROCHLORIDE TABLETS

{2} Receives Tentative Approval To Market Donepezil Hydrochloride Tablets - News, Search Jobs, Events News | News By Subject | News by Disease | News By Date | Search News PRINCETON, N.J., Feb. 25 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Donepezil Hydrochloride Tablets, 5 mg and 10 mg. Total annual market sales for Donepezil Hydrochloride Tablets, 5 mg and 10 mg, were $935.3 million (IMS - MAT: December 2004).Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries. ARICEPT (donepezil hydrochloride tablets)ARICEPT - donepezil hydrochloride tablet, film coated These highlights do not include all the information needed to use ARICEPT safely and effectively. See full prescribing information for ARICEPT.The higher dose of 10 mg did not provide a statistically significantly greater clinical benefit than 5 mg.